- Home
- SF vs ITCI Comparison
SF vs ITCI Comparison
Compare SF & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- ITCI
- Stock Information
- Founded
- SF 1890
- ITCI 2002
- Country
- SF United States
- ITCI United States
- Employees
- SF N/A
- ITCI N/A
- Industry
- SF Investment Bankers/Brokers/Service
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- SF Finance
- ITCI Health Care
- Exchange
- SF Nasdaq
- ITCI Nasdaq
- Market Cap
- SF 12.0B
- ITCI 13.5B
- IPO Year
- SF N/A
- ITCI N/A
- Fundamental
- Price
- SF $93.87
- ITCI $131.81
- Analyst Decision
- SF Hold
- ITCI Buy
- Analyst Count
- SF 8
- ITCI 13
- Target Price
- SF $117.71
- ITCI $106.58
- AVG Volume (30 Days)
- SF 867.9K
- ITCI 2.0M
- Earning Date
- SF 04-23-2025
- ITCI 05-06-2025
- Dividend Yield
- SF 1.96%
- ITCI N/A
- EPS Growth
- SF 46.03
- ITCI N/A
- EPS
- SF 6.25
- ITCI N/A
- Revenue
- SF $4,944,918,000.00
- ITCI $680,852,000.00
- Revenue This Year
- SF $16.65
- ITCI $40.64
- Revenue Next Year
- SF $9.85
- ITCI $58.53
- P/E Ratio
- SF $15.02
- ITCI N/A
- Revenue Growth
- SF 14.36
- ITCI 46.62
- 52 Week Low
- SF $73.51
- ITCI $64.09
- 52 Week High
- SF $120.64
- ITCI $131.87
- Technical
- Relative Strength Index (RSI)
- SF 37.70
- ITCI 85.59
- Support Level
- SF $96.55
- ITCI $131.19
- Resistance Level
- SF $102.78
- ITCI $131.79
- Average True Range (ATR)
- SF 2.94
- ITCI 0.13
- MACD
- SF 0.39
- ITCI -0.41
- Stochastic Oscillator
- SF 22.59
- ITCI 91.18
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 60% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.